COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model

COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer

COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis

CBRE Arranges Expansion Lease for Cour Pharmaceuticals

Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.

COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy

Specificity of the T Cell Response to Protein Biopharmaceuticals

Protein biopharmaceuticals (BPs) have revolutionized the treatment of many diseases and their […]

U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC)

FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals

Today, COUR Pharma announced the U.S. Food and Drug Administration accepted its […]

COUR’s intracellular T-cell reprograming leads to a reduction to anti-drug and neutralizing antibodies